Decheng Capital Management III (Cayman)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$9.13M	Hold	78,900	–	–	3.05%	12
2023 Q2	$8.11M	Hold	78,900	–	–	2.55%	11
2023 Q1	$8.61M	Hold	78,900	–	–	3.47%	10
2022 Q4	$8.98M	Hold	78,900	–	–	3.36%	11
2022 Q3	$4.88M	Buy	78,900 +23,500	+42%	+$1.64M	1.77%	16
2022 Q2	$4.42M	Buy	+55,400	New	+$5.25M	1.68%	14

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s HZNP Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q3 2023 at 78,900 shares worth $9.13M. The position accounts for 3.05% of the portfolio, ranked #12.

Decheng Capital Management III (Cayman) first reported a position in HZNP in Q2 2022 and has held it in 6 quarters since. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Decheng Capital Management III (Cayman) held 78,900 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $9.13M as of Q3 2023.
Decheng Capital Management III (Cayman) left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q3 2023.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 3.05% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #12 holding.
Decheng Capital Management III (Cayman) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and has held it in 6 quarters since.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.